Anatara Lifesciences (ANR) Stock Overview
Engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ANR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Anatara Lifesciences Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.013 |
| 52 Week High | AU$0.059 |
| 52 Week Low | AU$0.004 |
| Beta | 0.57 |
| 1 Month Change | 0% |
| 3 Month Change | 18.18% |
| 1 Year Change | -71.74% |
| 3 Year Change | -62.86% |
| 5 Year Change | -93.16% |
| Change since IPO | -96.90% |
Recent News & Updates
Shareholder Returns
| ANR | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 8.3% | 0.8% | 0.5% |
| 1Y | -71.7% | -32.1% | 2.4% |
Return vs Industry: ANR underperformed the Australian Biotechs industry which returned -32.5% over the past year.
Return vs Market: ANR underperformed the Australian Market which returned 2.4% over the past year.
Price Volatility
| ANR volatility | |
|---|---|
| ANR Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in AU Market | 18.9% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: ANR's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: ANR's weekly volatility has decreased from 24% to 14% over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | David Brookes | anataralifesciences.com |
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company’s products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral medication to assist weight reduction and control.
Anatara Lifesciences Ltd Fundamentals Summary
| ANR fundamental statistics | |
|---|---|
| Market cap | AU$4.08m |
| Earnings (TTM) | -AU$1.95m |
| Revenue (TTM) | AU$969.46k |
Is ANR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANR income statement (TTM) | |
|---|---|
| Revenue | AU$969.46k |
| Cost of Revenue | AU$1.60m |
| Gross Profit | -AU$633.97k |
| Other Expenses | AU$1.32m |
| Earnings | -AU$1.95m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0062 |
| Gross Margin | -65.39% |
| Net Profit Margin | -201.63% |
| Debt/Equity Ratio | 76.0% |
How did ANR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/08 05:08 |
| End of Day Share Price | 2025/12/08 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Anatara Lifesciences Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shane Storey | Canaccord Genuity Historic (Wilsons Advisory and Stockbroking Ltd. |
| Paul Jensz | PAC Partners Securities Pty. Ltd. |